ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 358

Immunophenotypic Analysis of T Cells from Leukemia Patients with Immune Checkpoint Inhibitor-Associated Respiratory Complications

Sang Kim1, Vickie Shannon2, Ajay Sheshardi2, Hagop Kantarjian3, Guillermo Garcia-Manero3, Farhad Ravandi3, Aung Naing4, Padmanee Sharma5, Jin Im6, Wilfredo Ruiz Vazquez6, Adi Diab7, Dimitrios Kontoyiannis8, Andrew Futreal9 and Naval Daver3, 1General Internal Medicine, MD Anderson Cancer Center, Houston, TX, 2Pulmonary Medicine, MD Anderson Cancer Center, Houston, TX, 3Leukemia, MD Anderson Cancer Center, Houston, TX, 4Investigational Cancer Therapeutics, MD Anderson Cancer Center, Houston, TX, 5Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, TX, 6Stem Cell Transplantation, MD Anderson Cancer Center, Houston, TX, 7Melanoma Medical Oncology, Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, Houston, TX, 8Infectious Diseases, MD Anderson Cancer Center, Houston, TX, 9Genomic Medicine, MD Anderson Cancer Center, Houston, TX

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Immunotherapy, inflammation and respiratory disease, T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster I: Checkpoint Inhibitors, Retroperitoneal Fibrosis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Immune checkpoint inhibitor (ICI)-based combinations are showing encouraging results in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) treatment; however, ICIs can cause immune-related adverse events, inflammation of one or few organs. Ten percent of AML or MDS patients receiving an ICI develop respiratory complications, one of life-threatening immune related adverse events (irAEs) induced by ICIs. Understanding the mechanism by which pneumonitis occurs is important in risk stratification and early detection, however, this information remains elusive.

Methods: We performed flow cytometry and T cell receptor (TCR) analysis of cells isolated from bronchial alveolar lavage (BAL) fluid and matched blood from seven AML or MDS patients, who received ICI therapy, developed respiratory symptoms, and underwent a standard-of-care bronchoscopy (hereafter, ICI group). In parallel, we collected 22 BAL and matched blood samples from AML or MDS patients who had never been received an ICI. Six of these patients were determined to have documented bacterial or fungal pneumonia, based on the independent review of two independent pulmonologists and an infectious disease specialist, and served as controls.

Results:

The ICI group patients developed respiratory symptoms 42.6 ± 62.6 days (mean ± SD) after the first infusion of an ICI. TCR analysis showed that BAL T cells from the ICI group were clonally expanded compared to control BAL T cells. Immunophenotyping revealed that BAL CD8+ T cells in the ICI group were expanded (ICI vs. control, % within live lymphocytes, mean ± SD, 24.1 ± 18.3 vs. 5.8 ± 1.2, P = 0.02). These cells were most likely effector memory or terminally differentiated effector memory cells. Compared to BAL CD4+ T cells in controls, Th1.17 (CXCR3hi CCR6hi) CD4+ T cells, known to be implicated in autoimmune diseases, were expanded in the ICI group (% within live CD4+ T cells, 49.4 ± 19.5 vs. 16.8 ± 11.0, P = 0.03). IL-17 producing CD4+ T cells were also expanded in BAL in the ICI group (% within non-regulatory CD4+ T cells, 15.4 ± 4.8 vs. 7.6 ± 2.8, P = 0.03). Although statistical significance was not reached, Th17 cell-related cytokines were detected in BAL fluid in ICI group at a frequency similar to, or slightly greater than controls. Immunophenotypic characteristics of T cells in blood were comparable between the ICI group and control.

Conclusion:

These results suggest that Th1.17 CD4+ T cells may play a central role in ICI-associated pneumonitis. Understanding the biology of the Th1.17 CD4+ T cell will provide us therapeutic targets and reliable biomarkers of ICI-associated pneumonitis. Furthermore, characterization of Th1.17 CD4+ T cells may offer better insights into pneumonitis secondary to the autoimmune diseases.


Disclosure: S. Kim, None; V. Shannon, None; A. Sheshardi, None; H. Kantarjian, None; G. Garcia-Manero, None; F. Ravandi, None; A. Naing, None; P. Sharma, None; J. Im, None; W. Ruiz Vazquez, None; A. Diab, None; D. Kontoyiannis, None; A. Futreal, None; N. Daver, None.

To cite this abstract in AMA style:

Kim S, Shannon V, Sheshardi A, Kantarjian H, Garcia-Manero G, Ravandi F, Naing A, Sharma P, Im J, Ruiz Vazquez W, Diab A, Kontoyiannis D, Futreal A, Daver N. Immunophenotypic Analysis of T Cells from Leukemia Patients with Immune Checkpoint Inhibitor-Associated Respiratory Complications [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/immunophenotypic-analysis-of-t-cells-from-leukemia-patients-with-immune-checkpoint-inhibitor-associated-respiratory-complications/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immunophenotypic-analysis-of-t-cells-from-leukemia-patients-with-immune-checkpoint-inhibitor-associated-respiratory-complications/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology